Current Report Filing (8-k)
June 12 2018 - 6:09AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 11, 2018
Protagenic
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-51353
|
|
06-1390025
|
(State
or other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
149
Fifth Ave, Suite 500, New York, NY
|
|
10010
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
212-994-8200
Registrant’s
telephone number, including area code:
Not
Applicable
|
(Former
name or former address if changed since last report.)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2 of the Securities Exchange Act of 1934.
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Events.
On
June 11, 2018, Protagenic Therapeutics, Inc. issued a press release announcing that the naturally-occurring brain peptide upon
which its lead drug compound, PT00114, is based, known scientifically as teneurin C-terminal associated peptide (TCAP), has been
featured in three peer-reviewed publications in major scientific journals. A copy of this press release is filed as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Protagenic
Therapeutics, Inc.
|
|
|
|
|
By:
|
/s/
Alexander Arrow
|
|
|
Alexander
K. Arrow, MD, CFA
|
|
|
Chief
Financial Officer
|
Date:
June 11, 2018
|
|
|
EXHIBIT
INDEX